Moreover, APC mice with global suppression of TGF-β signaling present with an overall increase in inflammation and tumor formation, suggesting that CRC patients treated with TGF-β inhibitors may have a worse outcome by enhancing inflammatory responses [214]. The gene discussed is TGFB1; the disease is colorectal carcinoma.